Orforglipron’s UK authorization is covered in a regulatory-first roundup, explaining what this approval milestone means for patients and market access.
Key Takeaways
- MHRA authorised orforglipron as an oral GLP-1 for weight management and type 2 diabetes
- Orforglipron is not currently available on the NHS pending NICE cost-effectiveness assessment
- As a small molecule tablet, orforglipron could ease peptide manufacturing constraints and supply shortages